Pharmacotherapy of Cognitive Impairment in Alzheimer's Disease: A Review

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Journal of Geriatric Psychiatry and Neurology

• Publication date

  1995-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/089198879500800202PMID 7794480
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• TRH attenuates scopolamine-induced memory impairment in humans

  2005cited by this paper
• Acute effects of high-dose thyrotropin releasing hormone infusions in Alzheimer's disease

  2004cited by this paper
• Intravenous nicotine in Alzheimer's disease: a pilot study

  2004cited by this paper
• Senile dementia of the Alzheimer type treated with aniracetam: a new nootropic agent

  2004cited by this paper
• Aluminum and Alzheimer's disease.

  1995cited by this paper
• Tacrine for Alzheimer's disease.

  1993cited by this paper
• [Affective disorders in the fourth edition of the classification of mental disorders prepared by the American Psychiatric Association -- diagnostic and statistical manual of mental disorders].

  1993cited by this paper
• Tacrine in Alzheimer's disease

  1992cited by this paper
• A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.

  1992cited by this paper
• A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.

  1992cited by this paper
• Pharmacologic models of Alzheimer's disease.

  1991cited by this paper
• Alzheimer's disease : basic mechanisms, diagnosis and therapeutic strategies

  1991cited by this paper
• Intramuscular desferrioxamine in patients with Alzheimer's disease.

  1991cited by this paper
• Drug treatment of Alzheimer's disease.

  1991cited by this paper
• Tacrine in Alzheimer's disease.

  1991cited by this paper
• Effects of a MAO-B inhibitor in the treatment of Alzheimer disease.

  1991cited by this paper
• Monoamine Oxidase and Dementia: Treatment with an Inhibitor of MAO-B Activity

  1990cited by this paper
• Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study.

  1990cited by this paper
• Tetrahydroaminoacridine and lecithin for Alzheimer's disease.

  1990cited by this paper
• Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia.

  1990cited by this paper
• Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine.

  1990cited by this paper
• Effects of metrifonate, a long‐acting cholinesterease inhibitor, in alzheimer disease: Report of an open trial

  1990cited by this paper
• DGAVP (Org 5667) in early Alzheimer's disease patients

  1990cited by this paper
• The Clinical Efficacy of Citalopram in Treatment of Emotional Disturbances in Dementia Disorders a Nordic Multicentre Study

  1990cited by this paper
• AF102B: rational treatment strategy for Alzheimer's disease: recent advances.

  1990cited by this paper
• Anti-inflammatory drugs and Alzheimer disease.

  1990cited by this paper
• Neurochemical actions of "nootropic drugs".

  1990cited by this paper
• GM-1 treatment of Alzheimer's disease. A pilot study of safety and efficacy.

  1990cited by this paper
• Cytochrome oxidase deficiency in Alzheimer's disease

  1990cited by this paper
• Induction of Alzheimer antigens by an uncoupler of oxidative phosphorylation.

  1990cited by this paper
• Double-blind, placebo controlled study of acetyl-l-carnitine in patients with Alzheimer's dementia.

  1990cited by this paper
• Selegiline in the treatment of mild to moderate Alzheimer-type dementia.

  1990cited by this paper
• Neuropsychological effects of L-deprenyl in Alzheimer's type dementia.

  1990cited by this paper
• Lack of efficacy of hydergine in patients with Alzheimer's disease.

  1990cited by this paper
• Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported.

  1989cited by this paper
• Intracerebroventricular bethanechol chloride infusion in Alzheimer's disease. Results of a collaborative double-blind study.

  1989cited by this paper
• Milacemide, a glycine prodrug, enhances performance of learning tasks in normal and amnestic rodents.

  1989cited by this paper
• Current Research in Alzheimer Therapy

  1989cited by this paper
• Hyperresponsivity to the serotonin agonist m-chlorophenylpiperazine in Alzheimer's disease. A controlled study.

  1989cited by this paper
• Double-blind trial of imipramine in Alzheimer's disease patients with and without depression.

  1989cited by this paper
• Acute effects of oral pyridostigmine on memory and cognitive function in SDAT.

  1989cited by this paper
• Guanfacine treatment of Alzheimer's disease.

  1989cited by this paper
• Clonidine treatment of Alzheimer's disease.

  1989cited by this paper
• Nerve growth factor as a potential treatment in Alzheimer's disease.

  1989cited by this paper
• Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease.

  1989cited by this paper
• Nicergoline in Mild to Moderate Dementia: A Multicenter, Double‐Blind, Placebo‐Controlled Study

  1989cited by this paper
• Pyritinol treatment of SDAT patients: evaluation by psychiatric and neurological examination, psychometric testing and rCBF measurements.

  1989cited by this paper
• The Safety and Lack of Efficacy of Vinpocetine in Alzheimer's Disease

  1989cited by this paper
• Multicenter trial of naloxone in alzheimer's disease

  1989cited by this paper
• Effects of 9-amino-1,2,3,4-tetrahydroacridine (THA), a potential drug for treatment of Alzheimer's disease, on the physical state of human erythrocyte membranes.

  1989cited by this paper
• Chronic Oral Physostigmine Without Lecithin Improves Memory in Alzheimer's Disease

  1989cited by this paper
• GEOGRAPHICAL RELATION BETWEEN ALZHEIMER'S DISEASE AND ALUMINIUM IN DRINKING WATER

  1989cited by this paper
• The amyloid proteins of Alzheimer's disease as potential targets for drug therapy.

  1989cited by this paper
• Geographical relation between Alzheimer's disease and aluminum in drinking water.

  1989cited by this paper
• ALUMINUM AS A PATHOGENIC FACTOR IN SENILE DEMENTIA OF ALZHEIMER TYPE: ION SPECIFIC CHELATION

  1989cited by this paper
• No response to high‐dose muscarinic agonist therapy in Alzheimer's disease

  1988cited by this paper
• Intraventricular bethanechol infusion for Alzheimer's disease

  1988cited by this paper
• Multiple-dose arecoline infusions in Alzheimer's disease.

  1988cited by this paper
• Tranylcypromine Compared with L‐Deprenyl in Alzheimer's Disease

  1988cited by this paper
• Thiamine and Alzheimer's disease. A pilot study.

  1988cited by this paper
• Phosphatidylserine in the treatment of Alzheimer's disease: results of a multicenter study.

  1988cited by this paper
• S-adenosyl-L-methionine in the treatment of Alzheimer's disease.

  1988cited by this paper
• 4-Aminopyridine in the treatment of Alzheimer's disease.

  1988cited by this paper
• Oral tetrahydroaminoacridine in the treatment of senile dementia, Alzheimer's type.

  1987cited by this paper
• Vinpocetine enhances retrieval of a step-through passive avoidance response in rats.

  1987cited by this paper
• The nerve growth factor 35 years later.

  1987cited by this paper
• A Controlled Double‐Blind Study of High‐Dose Dihydroergotoxine Mesylate (HydergineR) in Mild Dementia

  1987cited by this paper
• Interactions between oxiracetam, aniracetam and scopolamine on behavior and brain acetylcholine.

  1987cited by this paper
• Fee-for-service research on THA: an explanation.

  1987cited by this paper
• Induction of depression with oxotremorine in patients with Alzheimer's disease.

  1987cited by this paper
• Fee-for-service research on THA: an explanation.

  1987cited by this paper
• The effect of chronic hydergine treatment on the plasticity of synaptic junctions in the dentate gyrus of aged rats.

  1987cited by this paper
• Failure of nalmefene and estrogen to improve memory in Alzheimer's disease.

  1987cited by this paper
• Perspectives on the etiology of Alzheimer's disease.

  1987cited by this paper
• Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin.

  1987cited by this paper
• Somatostatin content and release measured in cerebral biopsies from demented patients.

  1987cited by this paper
• L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition.

  1987cited by this paper
• Lecithin and piracetam in Alzheimer's disease.

  1987cited by this paper
• Serum calcium levels in Alzheimer's disease: A finding and an aetiological hypothesis

  1987cited by this paper
• Anatomy of cholinesterase inhibition in Alzheimer's disease: Effect of physostigmine and tetrahydroaminoacridine on plaques and tangles

  1987cited by this paper
• Multiple Nutrients in the Treatment of Alzheimer's Disease

  1987cited by this paper
• Cerebrospinal Fluid Vasopressin, Oxytocin, sopressin, Oxytoc in Alzheimer's Diseasβ-Endorphin

  1986cited by this paper
• Localization of nerve growth factor receptors in cholinergic neurons of the human basal forebrain.

  1986cited by this paper
• The cholinergic hypothesis--ten years on.

  1986cited by this paper
• Desamino-D-arginine-vasopressin (DDAVP) in Alzheimer's disease.

  1986cited by this paper
• Aluminum and Alzheimer's disease.

  1986cited by this paper
• Therapeutic effects of huperzine A on the aged with memory impairment

  1986cited by this paper
• Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type.

  1986cited by this paper
• SEROTONINERGIC TREATMENT OF SCREAMING AND BANGING IN DEMENTIA

  1986cited by this paper
• Pharmacology of thyrotropin-releasing hormone.

  1986cited by this paper
• Cerebrospinal fluid vasopressin, oxytocin, somatostatin, and beta-endorphin in Alzheimer's disease.

  1986cited by this paper
• Decreased cerebral blood flow precedes multi‐infarct dementia, but follows senile dementia of Alzheimer type

  1986cited by this paper
• Naloxone and Alzheimer's disease. Cognitive and behavioral effects of a range of doses.

  1986cited by this paper
• Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type.

  1986cited by this paper
• Vasopressin in Alzheimer's disease: A study of postmortem brain concentrations

  1986cited by this paper
• Nicotinic acetylcholine binding sites in Alzheimer's disease.

  1986cited by this paper
• GABA-agonist therapy for Alzheimer's disease.

  1986cited by this paper
• Neuropeptides in neurologic and psychiatric disease.

  1986cited by this paper
• Memantine in the treatment of senile dementia of the Alzheimer type.

  1986cited by this paper
• A double‐blind comparison of alaproclate and placebo in the treatment of patients with senile dementia

  1985cited by this paper

• Synthesis and characterisation of novel phenanthroline quinone derivatives and their evaluation as Alzheimer's disease therapeutic active ingredients

  2018cites this paper
• The role of nitric oxide in the object recognition memory.

  2015cites this paper
• Enzyme Inhibitors Involved in the Treatment of Alzheimer’s Disease

  2014cites this paper
• Recovery following anterior thalamic lesions.

  2009cites this paper
• The nitric oxide (NO) donor molsidomine antagonizes scopolamine and L-NAME-induced performance deficits in a spatial memory task in the rat.

  2009cites this paper
• Cell adhesion proteins altered by 17beta estradiol and parathion in breast epithelial cells.

  2008cites this paper
• Gene and Protein Expressions Induced by 17β-estradiol and Parathion in Cultured Breast Epithelial Cells

  2007cites this paper
• Gene expression signature of parathion-transformed human breast epithelial cells.

  2007cites this paper
• Gene and protein expressions induced by 17beta-estradiol and parathion in cultured breast epithelial cells.

  2007cites this paper
• Nitric oxide donor molsidomine attenuates psychotomimetic effects of the NMDA receptor antagonist MK‐801

  2006cites this paper
• The nitric oxide donor molsidomine antagonizes age-related memory deficits in the rat.

  2005cites this paper
• Molsidomine antagonizes L-NAME-induced acquisition deficits in a recognition memory task in the rat.

  2003cites this paper
• Molsidomine attenuates N(omega)-nitro-L-argininemethylester-induced deficits in a memory task in the rat.

  2002cites this paper
• Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy

  2000cites this paper
• Clinical and radiological determinants of prestroke cognitive decline in a stroke cohort

  1999cites this paper
• Strategies That Support Declining Cholinergic Neurotransmission in Alzheimer’s Disease Patients

  1999cites this paper
• Complementary and Alternative Medicines for Alzheimer's Disease

  1998cites this paper
• PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

  1998cites this paper
• Providing dental care for patients diagnosed with Alzheimer's disease.

  1997cites this paper
• The Comparative Amnestic Effects of Midazolam, Propofol, Thiopental, and Fentanyl at Equisedative Concentrations

  1997cites this paper
• Preexisting dementia in stroke patients. Baseline frequency, associated factors, and outcome.

  1997cites this paper
• The role of the dorsal raphe-serotonergic system and cholinergic receptors in the modulation of working memory.

  1997cites this paper
• Cognitive Enhancement

  1996cites this paper
• Negative symptoms in Alzheimer's disease.

  1996cites this paper
• Maximizing function in Alzheimer's disease: what role for tacrine?

  1996cites this paper